Contribute Try STAT+ Today

In an apparent victory for Purdue Pharma, preliminary voting shows most creditors are in favor of its controversial bankruptcy plan, an outcome that, if confirmed, suggests the company and its infamous owners are closer to resolving sweeping litigation filed over its role in the opioid crisis.

More than 95% of the 120,000-plus votes submitted were in favor of the bankruptcy proposal and nearly 97% of almost 5,000 state and local governmental creditors voted to accept the plan, according to a statement issued by the company that cited a court filing. It is not clear how many were entitled to vote but did not, though. The final tally will be made public by Aug. 2, ahead of a scheduled hearing in a U.S. bankruptcy court to confirm the proposal.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Create a display name to comment

This name will appear with your comment